Novo Nordisk shares tumble 11% after company forecasts sales declines this year

Core Viewpoint - Novo Nordisk's U.S. shares dropped significantly after the company projected a decline in sales and profit growth for the year, indicating a sales hit ahead of its quarterly report [1][2] Group 1: Sales and Profit Forecast - In 2025, Novo Nordisk reported a 10% increase in sales and a 6% increase in operating profit, aligning with the company's guidance [2] - For 2026, the company anticipates a sales decline between 5% and 13% at constant exchange rates, reflecting expectations for growth in International Operations but a decline in U.S. Operations [2] Group 2: Market Competition and Product Strategy - Novo Nordisk is focusing on its Wegovy pill and the next-generation weight-loss injectable CagriSema to regain market share in the U.S. and improve its stock price [3] - The company launched the oral version of Wegovy in the U.S. in early January, and its performance is being closely monitored, especially with Eli Lilly expected to introduce its own weight loss pill in the first half of 2026 [4] Group 3: Investor Sentiment - Investors are keen to see how Novo Nordisk capitalizes on its lead in the direct-to-patient channel, particularly in closing the gap with Eli Lilly in 2025 [5]